Fig. 01 -

Title Slide

Fig. 02 -

Cost - COPD Exacerbations

Fig. 03 -

Economic Burden

Fig. 04 -

Performance Targets

Fig. 05 -

Human Cost

Fig. 06 -

Detrimental Effects

Fig. 07 -

Prevention Strategies

Fig. 08 -

Skeletal muscle dysfunction

Fig. 09 -

Cochrane systematic review

Fig. 10 -

Intervention group

Fig. 11 -

Failure of treatment

Fig. 12 -

Early Interventions

Fig. 13 -

NIHR Portfolio (UKCRN)

Fig. 14 -

1 UK-HoT-HMV Trial

Fig. 15 -

2 UK-HoT-HMV Trial

Fig. 16 -

3 UK-HoT-HMV Trial

Fig. 17 -

4 UK-HoT-HMV Trial

Fig. 18 -

5 UK-HoT-HMV Trial

Fig. 19 -

6 UK-HoT-HMV Trial

Fig. 20 -

Longterm Interventions

Fig. 21 -

LTOT

Fig. 22 -

Longterm Interventions

Fig. 23 -

Benefit/Lack of Benefit

Fig. 24 -

Why the contrast?

Fig. 25 -

Risk Stratification

Fig. 26 -

Myotrace Programme

Fig. 27 -

NEJM 2012

Fig. 28 -

Biomarker

Fig. 29 -

Serum Biomarkers

Fig. 30 -

1 Advanced Physiological Biomarker

Fig. 31 -

2 Advanced Physiological Biomarker

Fig. 32 -

3 Advanced Physiological Biomarker

Fig. 33 -

4 Advanced Physiological Biomarker

Fig. 34 -

Treatment Failure

Fig. 35 -

Treatment Failure

Fig. 36 -

Treatment Success

Fig. 37 -

Diaphram Electromyography

Fig. 38 -

Myotrace

Fig. 39 -

EMGpara

Fig. 40 -

Sniff Manoeuvre

Fig. 41 -

Neural Respiratory Drive

Fig. 42 -

1 Results

Fig. 43 -

2 Results

Fig. 44 -

1 Detecting Clinical Deterioration

Fig. 45 -

2 Detecting Clinical Deterioration

Fig. 46 -

1 Predicting Re-admission

Fig. 47 -

2 Predicting Re-admission

Fig. 48 -

Summary

Fig. 49 -

Personalized Medicine

Fig. 50 -

Early Discharge

Fig. 51 -

Telehealth

Fig. 52 -

Meta-analysis

Fig. 53 -

European Commission

Fig. 54 -

1 Conclusion

Fig. 55 -

2 Conclusion

Fig. 56 -

1 COST & CLINICAL Effectiveness

Fig. 57 -

2 COST & CLINICAL Effectiveness

Fig. 58 -

Review

Fig. 59 -

Sources

Fig. 60 -

Thank you.